Leukocyte reduction of blood components: public policy and new technology.
Dzik
S
S
Blood Transfusion Service, Massachusetts General Hospital, Boston 02114, USA.
Aubuchon
J
J
Jeffries
L
L
Kleinman
S
S
Manno
C
C
Murphy
M F
MF
Popovsky
M A
MA
Sayers
M
M
Silberstein
L E
LE
Slichter
S J
SJ
Vamvakas
E C
EC
D000276:Adjuvants, Immunologic; D001781:Blood Component Removal / Q000009:adverse effects / Q000191:economics / Q000592:standards*; D016913:Blood Component Transfusion / Q000009:adverse effects / Q000191:economics / Q000592:standards*; D003365:Costs and Cost Analysis; D007562:Creutzfeldt-Jakob Syndrome / Q000517:prevention & control; D005060:Europe; D006801:Humans; D007107:Immune System / Q000503:physiopathology; D007962:Leukocytes / Q000276:immunology*; D011640:Public Policy; D014481:United States
D000276:Adjuvants, Immunologic